Inquiry Basket
Polymer-Based RNA Delivery Solutions
RNA Drug Delivery Solutions
BOC Sciences provides polymer-based RNA drug delivery solution development services for mRNA, siRNA, saRNA, miRNA, ASO, RNA oligonucleotides, and RNA-polymer systems, supporting carrier screening, RNA loading, polymer modification, nanoparticle formulation, polyplex development, characterization, release evaluation, and formulation optimization.
Integrated RNA Delivery Development Support
Our RNA delivery support connects payload properties, polymer carrier design, formulation screening, analytical characterization, and optimization guidance for research-stage RNA delivery development.
- RNA payload property review and carrier feasibility assessment
- Polyplex, nanoparticle, nanogel, polymer-lipid hybrid, and conjugate strategy design
- RNA loading, encapsulation, integrity, size, zeta potential, and morphology characterization
- Formulation optimization based on RNA stability, carrier performance, and release goals
Why RNA Delivery Requires Engineered Polymer Systems
RNA payloads differ substantially in size, charge density, secondary structure, chemical modification, degradation sensitivity, and intracellular activity requirements. Small RNAs such as siRNA, miRNA, and ASO often require strong protection and controlled release, while mRNA and saRNA require carrier systems that can protect long RNA strands, maintain integrity, support cytosolic release, and avoid formulation conditions that damage RNA structure.
Polymer-based RNA delivery systems can be engineered to provide charge interaction, steric shielding, biodegradable release, hydrophilic stabilization, surface modification, and responsive carrier behavior. BOC Sciences helps clients translate RNA payload properties into testable polymer delivery strategies through carrier screening, material selection, formulation optimization, and data-driven interpretation.
RNA Protection and Integrity Preservation
RNA carriers must reduce degradation risks during preparation, handling, storage, and release evaluation. Carefully selected polymers and mild formulation conditions help protect RNA from RNase exposure, pH stress, shear-related damage, destabilizing solvent environments, and excessive electrostatic interaction that may compromise RNA integrity.
Carrier Architecture Matched to RNA Type
mRNA, siRNA, saRNA, miRNA, and ASO differ in length, rigidity, secondary structure, molecular weight, and release requirements. Carrier design should reflect these differences through appropriate polymer structure, particle architecture, complexation strength, surface chemistry, and formulation process selection.
Polymer Chemistry for Tunable Delivery Behavior
Polymer charge density, molecular weight, degradability, hydrophobicity, PEG shielding, responsive groups, and branching can be adjusted to tune RNA binding, colloidal stability, carrier disassembly, surface interactions, and release behavior. These variables help build RNA delivery systems around defined project goals.
Common Challenges in RNA Drug Delivery Development
RNA delivery development requires balancing RNA protection, carrier loading, colloidal stability, endosomal release, formulation compatibility, and analytical confirmation. Many formulation failures are not caused by a single factor but by interactions among RNA structure, carrier charge, polymer architecture, buffer composition, particle formation process, storage condition, and release environment.
RNA Instability and Degradation
RNA is sensitive to RNase exposure, temperature, pH, shear, and formulation stress. Long RNA payloads such as mRNA and saRNA require especially careful integrity protection.
Low Encapsulation or Complexation Efficiency
RNA length, concentration, secondary structure, polymer/RNA ratio, N/P ratio, and mixing process can all influence carrier formation and loading performance.
Particle Aggregation and Broad PDI
RNA-polymer systems may aggregate, broaden in particle size distribution, or shift surface charge during salt exposure, dilution, purification, storage, or freeze-thaw handling.
Endosomal Escape Limitation
RNA often needs efficient intracellular release. If the carrier binds RNA too strongly or lacks suitable escape behavior, productive delivery may remain limited.
Charge Balance and Compatibility Issues
Strongly cationic polymers can improve RNA binding but may also increase aggregation, nonspecific interaction, formulation stress, and compatibility concerns during screening.
Insufficient Characterization for Decision-Making
Without RNA integrity, size, PDI, zeta potential, loading, morphology, release, and stability data, it is difficult to identify the best optimization direction.
Our RNA Drug Delivery Solution Portfolio
BOC Sciences provides customized RNA delivery solution development across multiple polymer-based and polymer-assisted carrier formats. Instead of treating RNA delivery as a single formulation problem, we help clients evaluate carrier architecture according to RNA type, length, modification status, stability sensitivity, loading behavior, release requirement, and formulation constraints. The service portfolio covers RNA polyplexes, polymeric nanoparticles, polymer-lipid hybrids, nanogels, hydrogels, RNA-polymer conjugates, dendrimer-based carriers, and hyperbranched polymer platforms.
RNA Polyplex Platforms
RNA polyplex platforms use electrostatic interaction between RNA and cationic or ionizable polymers to form compact RNA-polymer complexes. They are especially useful for early feasibility screening, N/P ratio optimization, RNA binding evaluation, and small RNA carrier development.
- Cationic polymer-RNA complex development
- Polymer/RNA ratio and N/P ratio screening
- Charge density, branching, molecular weight, and buffer optimization
- Suitable for siRNA, miRNA, ASO, and selected mRNA feasibility studies
Polymeric RNA Nanoparticles
Polymeric nanoparticles support RNA protection, nanoparticle stabilization, surface modification, and controlled release exploration. They can be designed for mRNA, siRNA, saRNA, ASO, or RNA oligonucleotide projects requiring structured nanoscale carrier development.
- Polymeric RNA nanoparticle formulation and screening
- Encapsulation, adsorption, complexation, or core-shell loading strategies
- PLGA, PLA, PCL, PEGylated copolymers, and functional polymer systems
- Particle size, PDI, zeta potential, morphology, RNA loading, and release evaluation
Polymer-Lipid Hybrid Platforms
Polymer-lipid hybrid platforms combine polymer stabilization, surface engineering, and lipid-like assembly behavior. They are suitable for complex RNA payloads, multicomponent formulation comparison, or projects exploring alternatives when lipid-only systems show stability or release limitations.
- Polymer-lipid hybrid RNA carrier feasibility assessment
- Component ratio, mixing process, and surface shielding optimization
- Carrier stability, RNA loading, and release behavior evaluation
- Formulation troubleshooting for aggregation, leakage, or unstable particle properties
RNA Nanogels / Polymer Hydrogels
Polymer nanogels and RNA hydrogels provide hydrated polymer networks for RNA retention, mild release, and sustained exposure research models. These systems are designed around crosslinking density, swelling behavior, mesh size, diffusion pathways, and RNA integrity protection.
- RNA nanogel and hydrogel carrier development
- Crosslinking, swelling, and network structure adjustment
- RNA retention, diffusion, and release evaluation
- Mild aqueous formulation strategies for sensitive RNA payloads
RNA-Polymer Conjugate Platforms
RNA-polymer conjugate platforms are suitable when projects require defined linkage, functional polymer modification, responsive release, improved assembly behavior, or RNA-polymer hybrid architecture. They are especially useful when structural confirmation and purification are central requirements.
- RNA-polymer conjugation strategy design
- End-functional or side-chain functionalized polymer selection
- Linker chemistry, purification, and conjugation verification
- Assembly behavior, stability, and release-oriented evaluation
Dendrimer and Hyperbranched Polymer Platforms
Dendrimeric and hyperbranched polymers provide high functional group density, multivalent interaction, and compact carrier formation for RNA complexation and surface modification. These platforms require careful charge control, shielding, aggregation risk assessment, and release balance evaluation.
- Dendrimer-based RNA carrier screening
- Hyperbranched polymer-RNA complex formulation
- Surface modification and charge tuning
- RNA binding, particle stability, and release behavior evaluation
Need Help Selecting an RNA Delivery Carrier?
Share your RNA type, formulation goal, sample amount, and current development challenge. We can help compare polymer-based RNA carrier options and define a practical screening or optimization strategy.
Materials and Structural Design for RNA Delivery
RNA delivery performance is strongly influenced by polymer chemistry and carrier structure. Important design parameters include cationic group type, molecular weight, branching, degradable bonds, hydrophobic domains, PEG shielding, crosslinking density, surface functional groups, and the balance between RNA retention and release. BOC Sciences helps evaluate these variables to match polymer material behavior with RNA loading, stability, release, and formulation objectives.
Cationic and Ionizable Polymer Structures
Cationic and ionizable polymers support RNA complexation, charge tuning, and endosomal escape-oriented design. Their binding strength must be balanced with RNA release and colloidal stability.
- RNA binding through amine or ionizable functional groups
- Charge density and pH-responsive behavior adjustment
- Endosomal escape-oriented polymer structure design
- Release balance and aggregation risk evaluation
Biodegradable Polyesters and Functional Copolymers
Biodegradable polymers can support RNA nanoparticle formation, hybrid carrier design, and release-oriented formulation development through controlled degradation, diffusion, or matrix restructuring.
- PLGA, PLA, PCL, and PEG-PLGA carrier exploration
- Polymer degradation and RNA release relationship assessment
- Hydrophobic matrix and functional copolymer design
- Carrier stability and sustained release screening
PEGylated and Hydrophilic Shielding Polymers
PEGylated and hydrophilic polymers can reduce aggregation, improve dispersion, tune surface interactions, and support more stable RNA carrier behavior during formulation and handling.
- PEG derivatives for RNA carrier shielding
- Hydrophilic surface stabilization
- Protein interaction and colloidal behavior control
- Surface-modified carrier compatibility evaluation
Dendrimers and Hyperbranched Polymers
Highly branched architectures provide multivalent RNA interaction and modifiable surfaces, but charge density, structural rigidity, and aggregation behavior must be carefully controlled.
- Multivalent RNA binding and compact carrier formation
- Branching and generation-related structure evaluation
- Surface shielding and functional group modification
- Binding strength, particle stability, and release assessment
Natural and Polysaccharide-Based Polymers
Natural polymer derivatives can support mild carrier environments, hydrophilic matrix formation, and network-based RNA retention when selected and processed with suitable controls.
- Chitosan, alginate, gelatin, and related polymer evaluation
- Hydrophilic network and complex formation support
- pH, salt, and solubility compatibility assessment
- RNA retention and mild release behavior screening
Responsive Polymer Architectures
Responsive polymers can support triggered carrier disassembly, RNA release control, or environmentally sensitive behavior through pH, redox, enzyme-responsive, or degradable linkages.
- pH-responsive or redox-responsive polymer design
- Degradable linker and carrier disassembly planning
- RNA release tuning through responsive chemistry
- Custom polymer modification for functional carrier development
How to Select Polymer Platforms for Different RNA Drugs
RNA drugs often require polymer delivery strategies because RNA molecules are highly anionic, nuclease-sensitive, structurally fragile, and difficult to transport across cellular membranes. Different RNA drug categories vary in strand length, duplex or single-strand structure, modification status, intracellular release requirement, and tolerance to formulation stress.
| RNA Drugs | Key Delivery Challenges | Suitable Polymer Strategies | Key Evaluation Points |
|---|---|---|---|
| mRNA Therapeutics | Long strand length, nuclease sensitivity, shear sensitivity, limited cytosolic release, and need for translation-ready integrity | Polymeric nanoparticles, polymer-lipid hybrid carriers, biodegradable polyplexes, PEG-shielded polymer systems, responsive polymer carriers | RNA integrity, encapsulation efficiency, particle size, PDI, zeta potential, cytosolic release, translation-related performance, and formulation stability |
| mRNA Vaccines | Need for antigen expression, protection during delivery, immune-cell uptake, controlled immune stimulation, and storage stability | Polymer-lipid hybrid nanoparticles, cationic polymer nanoparticles, PLGA-based carriers, polymer-adjuvant co-delivery systems, injectable hydrogels | mRNA integrity, antigen expression potential, particle stability, immune-cell interaction, release timing, adjuvant compatibility, and storage behavior |
| siRNA Drugs | Small duplex structure, rapid nuclease degradation, charge repulsion, renal clearance, and need for efficient cytoplasmic release | Cationic polyplexes, polymeric nanoparticles, PEGylated polymer carriers, nanogels, polymer conjugates, polymer-lipid hybrid systems | siRNA binding, nuclease protection, loading efficiency, release behavior, gene silencing activity, cytocompatibility, and serum stability |
| miRNA Mimics and Inhibitors | Short RNA retention, off-target distribution, nuclease sensitivity, and need for controlled intracellular availability | Polyplex nanoparticles, nanogels, polymer conjugates, surface-shielded carriers, targeted polymer nanoparticles | RNA retention, release rate, cellular uptake, functional activity, leakage control, particle stability, and carrier interaction |
| shRNA Delivery Systems | Need for intracellular expression or delivery support, structural protection, carrier compaction, and controlled release behavior | Cationic polymer complexes, polymeric nanoparticles, dendrimer carriers, biodegradable polyplexes, polymer-hybrid carriers | Complex stability, RNA protection, intracellular release, knockdown efficiency, particle size, zeta potential, and cytocompatibility |
| saRNA Therapeutics | Very large RNA size, strong structural sensitivity, high formulation stress risk, and need for prolonged expression | Mild polymer-lipid hybrid carriers, protective polymeric nanoparticles, PEG-shielded polyplexes, biodegradable polymer carriers | saRNA integrity, loading efficiency, formulation stress, particle stability, release profile, expression duration, and degradation behavior |
| Antisense RNA Oligonucleotides | Short-chain diffusion, charge shielding needs, nuclease degradation, limited cellular uptake, and rapid systemic clearance | Polymer conjugates, nanogels, cationic polyplexes, hydrophilic polymer networks, PEGylated polymer carriers | Oligonucleotide binding, nuclease protection, release rate, hybridization activity, cellular uptake, leakage control, and biological-media stability |
| RNA Aptamers | Need for nuclease resistance, folding preservation, binding-site accessibility, reduced renal clearance, and controlled exposure | PEGylated polymer carriers, polymer conjugates, nanogels, surface-stabilized nanoparticles, hydrogel-based local delivery systems | Aptamer folding, target binding activity, nuclease protection, linker stability, release duration, carrier interaction, and recognition performance |
| CRISPR Guide RNA | Need for protection, intracellular delivery, co-delivery compatibility, endosomal escape, and preservation of editing function | Polyplex systems, polymeric nanoparticles, polymer-lipid hybrid carriers, responsive polymer complexes, nanogels | gRNA integrity, co-loading compatibility, complex stability, release synchronization, editing workflow compatibility, and cytocompatibility |
| RNA-Polymer Conjugates | Controlled linkage formation, purification complexity, altered charge balance, structural confirmation, and assembly behavior | End-functional polymer conjugation, PEG-RNA conjugates, side-chain functional polymers, degradable linker systems | Conjugation efficiency, linker integrity, molecular weight profile, purity, electrophoretic behavior, dispersity, and assembly stability |
How We Support RNA Delivery Development
BOC Sciences supports RNA delivery development from payload review and polymer carrier selection through formulation screening, RNA loading assessment, carrier characterization, release testing, and troubleshooting. Projects can be structured as early feasibility studies, carrier comparisons, polymer-lipid hybrid formulation, RNA-polymer conjugation, nanoparticle preparation, or focused optimization programs.
RNA Payload and Project Feasibility Assessment
We review RNA properties, sample conditions, formulation goals, and known challenges to define the most suitable polymer delivery starting point.
- RNA type, length, modification status, concentration, and buffer review
- Delivery objective and preferred carrier format assessment
- Available sample amount and formulation risk evaluation
- Initial polymer delivery strategy recommendation
Polymer Selection and Carrier Design
Polymer candidates are selected according to RNA binding requirements, release goals, structural sensitivity, and formulation compatibility.
- Cationic, ionizable, biodegradable, amphiphilic, and PEGylated polymer selection
- Molecular weight, charge density, hydrophobicity, and degradability planning
- Carrier architecture matched to mRNA, siRNA, saRNA, miRNA, or ASO
- Surface shielding, ligand-ready chemistry, and responsive release design
Formulation Screening and Optimization
Formulation variables are screened to improve RNA loading, carrier formation, colloidal stability, and release behavior.
- Polymer/RNA ratio and N/P ratio screening
- Buffer, pH, ionic strength, and mixing sequence optimization
- Size, PDI, zeta potential, and appearance comparison
- Storage, dilution, purification, and handling condition assessment
RNA Loading, Encapsulation and Release Evaluation
We evaluate whether RNA is effectively loaded, retained, protected, and released from the selected polymer carrier system.
- RNA complexation and encapsulation efficiency assessment
- RNA retention, leakage, and displacement testing
- In vitro release and sustained release evaluation
- RNA integrity and stability-related readout planning
Carrier Characterization
Carrier characterization helps interpret how polymer structure and formulation process influence RNA loading, stability, and release performance.
- DLS, zeta potential, and particle size distribution analysis
- TEM, SEM, or AFM morphology analysis where suitable
- HPLC, SEC/GPC, UV, fluorescence, or electrophoresis-based methods
- Surface properties, degradation, swelling, and stability evaluation
Formulation Troubleshooting and Redesign
Troubleshooting connects observed formulation problems with polymer design, carrier architecture, and process variables.
- Aggregation, broad PDI, and unstable zeta potential analysis
- Low loading, RNA leakage, or overly strong binding investigation
- Polymer chemistry, carrier architecture, and process adjustment
- Next-stage optimization plan and reporting
RNA Drug Delivery Development Workflow
Our workflow is designed to convert RNA delivery requirements into a structured development path covering payload review, stability assessment, carrier selection, formulation screening, analytical evaluation, and optimization recommendations. Each stage helps reduce unnecessary trial-and-error and clarifies whether a polymer-based carrier strategy can support RNA protection, loading, stability, and release goals.
Project Requirement Review
We begin by collecting information on RNA type, length, modification status, concentration, buffer composition, purity, available sample amount, preferred carrier format, target delivery objective, and known formulation challenges. This review also includes any existing data on RNA integrity, particle formation, loading behavior, or stability problems. The outcome is a clear project definition that guides feasibility planning, carrier comparison, and analytical endpoint selection.
RNA Property and Stability Assessment
RNA properties are assessed in relation to formulation stress, degradation sensitivity, secondary structure, chemical modification, and process compatibility. Long RNA payloads may require mild processing and careful integrity monitoring, while short RNA oligonucleotides may require improved retention or shielding. This step helps define handling requirements, buffer constraints, and the level of protection needed from the polymer carrier system.
Carrier Strategy Shortlisting
Candidate carrier approaches are shortlisted by comparing RNA polyplexes, polymeric nanoparticles, polymer-lipid hybrids, nanogels, hydrogels, dendrimer carriers, and RNA-polymer conjugates. Each option is evaluated for expected RNA binding, particle formation, stability, release behavior, preparation tolerance, and analytical feasibility. This stage helps prioritize carrier types that align with the RNA payload and the client's formulation objectives.
Polymer and Material Selection
Suitable polymers and supporting materials are selected based on charge density, ionizable behavior, molecular weight, degradability, hydrophilicity, branching, PEG shielding, and functional group chemistry. Material selection also considers whether the project requires rapid screening, stable encapsulation, responsive release, surface modification, or conjugation. The goal is to connect polymer structure with measurable RNA carrier performance.
Prototype Formulation Design
Prototype formulations are designed by defining polymer/RNA ratio, N/P ratio, buffer conditions, pH, ionic strength, concentration, mixing sequence, preparation method, and purification strategy. For hybrid or network systems, component ratio, crosslinking density, surface shielding, and carrier architecture may also be planned. This design stage creates a controlled formulation matrix for meaningful comparison.
Small-Scale Formulation Screening
Multiple candidate formulations are prepared at small scale to compare particle size, PDI, zeta potential, appearance, RNA loading, and short-term stability. Screening may examine how changes in polymer structure, formulation ratio, buffer composition, mixing conditions, or surface shielding affect carrier formation. The resulting data help identify promising formulations and eliminate unstable or poorly loaded systems.
RNA Integrity, Release and Stability Evaluation
Selected formulations are evaluated for RNA integrity, retention, leakage, release profile, and stability under relevant test conditions. Analytical approaches may include electrophoresis-based integrity checks, encapsulation or binding assays, release testing, fluorescence or UV-based quantification, and particle characterization after storage or dilution. This step helps determine whether the carrier protects RNA while still supporting useful release behavior.
Data Interpretation and Optimization Recommendation
Data are interpreted by connecting polymer chemistry, formulation variables, carrier structure, and analytical readouts. If issues such as aggregation, poor loading, RNA leakage, unstable zeta potential, or slow release are observed, we recommend targeted changes to polymer selection, carrier architecture, process conditions, or surface modification. The final recommendations define practical next steps for continued RNA delivery development.
Deliverables for RNA Drug Delivery Projects
Deliverables are customized according to project scope and may include RNA delivery strategy reports, polymer carrier selection rationale, prototype formulations, loading and encapsulation data, RNA integrity analysis, release profiles, characterization packages, and optimization recommendations. These outputs help clients compare delivery options and define practical next steps for RNA formulation development.
RNA Delivery Strategy Report
Summarizes RNA payload attributes, primary delivery challenges, candidate polymer carriers, formulation risks, and recommended development direction.
Polymer Carrier Selection Rationale
Explains how polymer charge, molecular weight, degradability, hydrophilicity, branching, and surface modification relate to RNA delivery goals.
Prototype RNA Delivery Formulations
May include RNA polyplexes, polymeric nanoparticles, nanogels, hydrogels, polymer-lipid hybrid carriers, dendrimer systems, or RNA-polymer conjugates.
Formulation Screening Data
Includes particle size, PDI, zeta potential, visual stability, RNA loading, encapsulation, binding, and initial formulation comparison data.
RNA Integrity and Release Data
Provides RNA integrity observations, release profiles, retention behavior, leakage risks, degradation findings, and stability-related interpretation.
Optimization Recommendations
Provides suggestions for polymer chemistry, formulation ratio, mixing process, surface shielding, purification method, and further characterization.
Why Choose BOC Sciences for RNA Drug Delivery Solutions
BOC Sciences combines polymer synthesis, custom polymer modification, polymer bioconjugation support, nanocarrier formulation, and characterization capabilities to support customized RNA delivery projects. The service emphasizes polymer chemistry, payload-specific carrier design, analytical interpretation, and formulation troubleshooting, helping clients move from uncertain RNA delivery problems to testable carrier strategies.
Polymer Chemistry-Driven RNA Carrier Design
Polymer charge, degradability, molecular weight, branching, functional groups, and surface chemistry can be adjusted for RNA payload requirements.
Multiple RNA Carrier Formats
We support RNA polyplexes, polymeric nanoparticles, polymer-lipid hybrids, nanogels, hydrogels, dendrimers, and RNA-polymer conjugates.
Integrated Characterization Support
Size, PDI, zeta potential, morphology, RNA loading, integrity, release, and stability data help explain formulation behavior.
Payload-Specific Development Logic
mRNA, siRNA, saRNA, miRNA, and ASO delivery strategies are customized according to length, structure, and release needs.
Connection with Conjugation and Surface Engineering
RNA carrier development can integrate polymer functionalization, PEGylation, polymer-nucleic acid conjugation, and surface modification.
Practical Project Communication
We translate RNA delivery challenges into defined formulation variables, characterization endpoints, sample requirements, and optimization recommendations.
Frequently Asked Questions
These questions address common considerations for polymer-based RNA delivery projects, including RNA type suitability, carrier selection, loading evaluation, conjugation support, hybrid carrier design, formulation troubleshooting, and sustained release development.
What types of RNA can be used in polymer-based delivery projects?
Polymer-based delivery projects may involve mRNA, siRNA, saRNA, miRNA, ASO, RNA oligonucleotides, or RNA-polymer conjugates. Feasibility depends on RNA length, modification status, concentration, buffer, integrity, and available sample amount. We evaluate these factors before recommending polyplex, nanoparticle, nanogel, hydrogel, hybrid, or conjugation-based carrier strategies.
What information is needed to start an RNA delivery project?
Useful starting information includes RNA type, length, sequence modification, concentration, buffer composition, purity, available quantity, preferred carrier format, target release behavior, and current formulation challenge. Existing data such as particle size, RNA integrity, loading efficiency, zeta potential, or stability observations can help define the most efficient screening plan.
Which polymer carriers are suitable for mRNA delivery?
mRNA delivery may be explored using polymeric nanoparticles, polymer-lipid hybrids, selected polyplexes, or responsive polymer systems. Because mRNA is large and degradation-sensitive, formulation design should prioritize mild preparation, integrity protection, stable encapsulation, and cytosolic release. Final carrier selection depends on RNA size, modification, buffer, and project goals.
How is siRNA delivery different from mRNA delivery?
siRNA is shorter and usually requires efficient duplex protection, charge shielding, and controlled release from compact carriers. mRNA is much larger and more structurally sensitive, so carrier systems must better protect integrity during preparation and handling. These differences affect polymer selection, formulation ratio, particle size targets, and analytical readouts.
Can polymer carriers be used together with lipid components?
Yes. Polymer-lipid hybrid carriers can combine polymer stabilization, surface engineering, and lipid-like assembly behavior. These systems may be useful when a project needs improved colloidal stability, tunable surface properties, or multicomponent formulation comparison. Component ratio, mixing sequence, buffer conditions, and RNA loading should be optimized experimentally.
How do you evaluate RNA loading or encapsulation?
RNA loading or encapsulation can be evaluated using encapsulation efficiency assays, binding or displacement tests, fluorescence-based quantification, UV analysis, electrophoresis-based integrity checks, release testing, DLS, and zeta potential measurement. The most suitable method depends on whether RNA is complexed, encapsulated, surface-associated, or covalently conjugated.
Can you support RNA-polymer conjugation?
Yes. RNA-polymer conjugation support can include RNA end-group compatibility review, polymer functionalization planning, linker chemistry selection, reaction condition design, purification guidance, and analytical confirmation. Potential strategies may involve click chemistry, thiol-maleimide coupling, amine-reactive chemistry, or other approaches compatible with the RNA modification and polymer structure.
Can RNA delivery systems be optimized for sustained release?
Yes. Sustained RNA release can be explored using biodegradable nanoparticles, nanogels, hydrogels, or responsive polymer carriers. Release behavior depends on RNA binding strength, polymer degradation, matrix swelling, diffusion pathways, and carrier stability. We typically evaluate release profiles together with RNA integrity, leakage risk, and particle characterization data.
Submit Your Drug Delivery Project Inquiry
Please share your RNA payload type, length, modification status, concentration, buffer composition, available sample amount, preferred carrier format, delivery objective, and current formulation challenge. Our team can help propose a polymer-based RNA delivery development strategy.
- mRNA, siRNA, saRNA, miRNA, ASO, and RNA-polymer delivery support
- Polyplex, nanoparticle, nanogel, hydrogel, polymer-lipid hybrid, and conjugate systems
- Polymer selection, RNA loading, encapsulation, characterization, and release testing
- Formulation troubleshooting and optimization recommendations
